teleo-codex/inbox/archive/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md

type	title	author	url	date	domain	secondary_domains	format	status	priority	tags	processed_by	processed_date	claims_extracted	enrichments_applied	extraction_model	extraction_notes
source	Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes	Journal of Managed Care & Specialty Pharmacy	https://www.jmcp.org/doi/10.18553/jmcp.2024.23332	2024-08-01	health		paper	processed	high	glp-1 adherence persistence discontinuation real-world-evidence obesity	vida	2026-03-11	glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md	GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md	anthropic/claude-sonnet-4.5	Three new claims extracted focusing on the persistence paradox (chronic use economics fail because of insufficient adherence, not excessive adherence), drug-specific variation (semaglutide 2.5x better than liraglutide), and income-driven discontinuation (affordability barrier even in commercially insured populations). Two enrichments applied to existing GLP-1 and value-based care claims, adding the critical 2-year persistence data (15%) that reframes the economic argument. The curator note was correct: this source reframes the 'chronic use inflation' concern—the actual problem is that most patients don't stay on long enough for downstream benefits to materialize.

Content

Real-world claims study of 125,474 patients initiating GLP-1 RAs for obesity (without type 2 diabetes) using commercial insurance data.

Persistence rates (non-diabetic obesity patients):

• 180 days: 46.3%
• 1 year: 32.3%
• 2 years: ~15%

By specific drug:

• Semaglutide: 47.1% at 1 year (highest)
• Liraglutide: 19.2% at 1 year (lowest)

Comparison with diabetic patients:

• Diabetic patients: 46.5% discontinue within 1 year (better than non-diabetic 64.8%)
• Danish registry: 21.2% discontinue within 12 months for T2D; ~70% discontinue within 2 years

Key factors associated with discontinuation:

• Insufficient weight loss
• Income level (lower income → higher discontinuation)
• Adverse events (GI side effects)
• Insurance coverage changes

Crucial nuance: Outcomes approach trial-level results when focusing on highly adherent patients. The adherence problem is not that the drugs don't work — it's that most patients don't stay on them.

Agent Notes

Why this matters: Adherence is THE binding constraint for the GLP-1 economic thesis. If only 32.3% of non-diabetic patients are still on GLP-1s at 1 year and ~15% at 2 years, the downstream savings that justify the cost never materialize for most patients. Under capitation, an MA plan pays for 12 months of GLP-1 ($2,940 at $245/month) for a patient who discontinues and regains weight — net cost with no benefit. What surprised me: The drug-specific variation is large — semaglutide at 47.1% vs. liraglutide at 19.2%. Oral formulations may change this further (removing injection barrier). The income correlation suggests access/affordability drives discontinuation as much as clinical factors. What I expected but didn't find: No analysis of how payment model affects persistence. Does being in an MA plan with care coordination improve adherence vs. FFS? No data on whether lifestyle interventions alongside medication improve persistence (directly relevant to BALANCE model design). KB connections: The existing GLP-1 claim cites 64.8% non-diabetic discontinuation at 1 year. This source provides the full persistence curve and the crucial 2-year data (15%). Extraction hints: The extractor should consider: "GLP-1 persistence at 2 years is only 15% for non-diabetic obesity patients, meaning the chronic use model fails not because patients choose indefinite use but because most cannot sustain it." This reframes the "inflationary chronic use" concern — the actual problem may be insufficient chronic use. Context: Commercial insurance population — different from Medicare (younger, fewer comorbidities). Medicare population may have different persistence patterns due to higher disease burden and stronger clinical indications.

Curator Notes (structured handoff for extractor)

PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 WHY ARCHIVED: The persistence data reframes the economic argument — the "chronic use" problem may actually be an "insufficient persistence" problem. Most patients don't stay on long enough for downstream benefits to materialize. EXTRACTION HINT: Focus on the paradox: chronic use makes GLP-1s expensive, but discontinuation eliminates the downstream savings that justify the cost. The economics only work if adherence is sustained AND the payer captures downstream savings.

Key Facts

• Study analyzed 125,474 commercially insured patients initiating GLP-1 RAs for obesity without type 2 diabetes
• Overall GLP-1 persistence: 46.3% at 180 days, 32.3% at 1 year, ~15% at 2 years
• Diabetic patients show better persistence: 53.5% at 1 year vs. 32.3% for non-diabetic
• Danish registry comparison: 21.2% of T2D patients discontinue within 12 months; ~70% discontinue within 2 years
• Key discontinuation factors: insufficient weight loss, income level, adverse events (GI), insurance coverage changes